FDA testing found undeclared diclofenac and dexamethasone in Ort-Flx and RX7 Articulaciones, with methocarbamol also detected in Ort-Flx.

The U.S. Food and Drug Administration is advising consumers not to purchase or use two products marketed for pain and musculoskeletal symptoms after laboratory testing identified multiple prescription drugs that were not disclosed on their labels.

On October 28, 2026, FDA issued separate public notifications for Ort-Flx and RX7 Articulaciones. Ort-Flx is promoted for pain, arthritis and allergies, while RX7 Articulaciones is promoted for joint and muscle pain. Both have been sold through various websites, including eBay, and may also be available in some retail stores. [1] [2]

FDA laboratory testing found:

The findings create a broader toxicology problem than hidden pain medication alone.

Both products contain an undeclared NSAID and an undeclared systemic corticosteroid, while Ort-Flx adds an unrecognized muscle relaxant exposure.

Why the Hidden Dexamethasone Matters

Dexamethasone is a potent corticosteroid used clinically for inflammatory and other medical conditions.

FDA warns that dexamethasone can suppress immune function and can contribute to hyperglycemia, muscle injury and psychiatric or behavioral effects. [1]

The more unusual concern in these two products is what may happen when repeated unrecognized corticosteroid exposure is stopped.

FDA explicitly advises people currently taking either Ort-Flx or RX7 Articulaciones to contact a healthcare professional to discontinue the product safely, and says the risk of corticosteroid withdrawal should be assessed by a clinician. [1] [2]

Approved dexamethasone labeling explains why duration matters: systemic corticosteroids can suppress the hypothalamic-pituitary-adrenal axis, and overly rapid withdrawal after sufficient exposure can produce adrenal insufficiency. The degree of risk depends on factors including dose and duration. [3]

That does not establish that users of these products have already developed adrenal suppression.

FDA has not disclosed how much dexamethasone the products contain or how long individual consumers used them.

For that reason, this News does not provide a generic taper schedule or advise abrupt discontinuation.

Hidden Diclofenac Creates an Additional NSAID Exposure

FDA also confirmed undeclared diclofenac in both products.

Diclofenac is a nonsteroidal anti-inflammatory drug. FDA warns that NSAIDs can increase the risk of serious cardiovascular events including heart attack and stroke and can cause gastrointestinal complications such as bleeding, ulceration and perforation. [1]

FDA also specifically notes that diclofenac can interact with other medicines, particularly other NSAID-containing products.

The hidden exposure therefore matters for medication reconciliation.

A consumer could unknowingly take Ort-Flx or RX7 Articulaciones together with another NSAID because diclofenac is not declared on the product label.

That does not mean FDA has documented GI bleeding, kidney injury or cardiovascular events in users of these two specific products.

The concern is the presence of an undeclared pharmacologically active NSAID and its established risk profile.

Ort-Flx Contains a Third Hidden Drug: Methocarbamol

Ort-Flx differs from RX7 Articulaciones because FDA also detected methocarbamol.

Methocarbamol is a centrally acting muscle relaxant that can cause:

• drowsiness;

• dizziness; and

• low blood pressure.

FDA warns that these effects may make driving or operating heavy machinery unsafe. [1]

Again, FDA has not published a methocarbamol concentration for Ort-Flx.

The laboratory finding establishes an undeclared exposure, not a known product-specific toxic dose.

Two Products, One Shared Hidden-Drug Pattern

The products are not analytically identical, but their core medication-safety problem is similar.

Ort-Flx: hidden diclofenac + dexamethasone + methocarbamol

RX7 Articulaciones: hidden diclofenac + dexamethasone

This combination creates three different blind spots:

NSAID exposure that may not be included in the patient's medication history;

corticosteroid exposure whose duration and dose are unknown and may complicate discontinuation after repeated use;

and, for Ort-Flx,

sedating muscle-relaxant exposure that the consumer may not know occurred.

This is different from a product containing a single undeclared analgesic.

FDA Has Issued Public Notifications, Not Recalls

The regulatory status should be described precisely.

FDA's current Health Fraud Product Database classifies both Ort-Flx and RX7 Articulaciones as Public Notification actions dated October 28. Neither is currently listed there as a recall. [4]

The agency advises consumers not to purchase or use either product.

FDA's broader Pain and Arthritis Products Containing Hidden Ingredients index also lists both products under October 28 notifications. [5]

Unless FDA or a manufacturer later announces a formal recall, the correct wording remains:

FDA public notification / warning — not recall.

No Ingredient Concentrations Have Been Published

A major limitation is the absence of quantitative testing information.

FDA's public notices do not disclose:

• the amount of diclofenac;

• the amount of dexamethasone;

• the amount of methocarbamol in Ort-Flx;

• the number of doses a typical consumer may have taken; or

• product-specific adverse-event counts.

That prevents several conclusions.

The public data do not support calculating an NSAID dose, estimating a corticosteroid-equivalent exposure, determining whether adrenal suppression occurred in an individual user, or predicting the magnitude of methocarbamol-related sedation.

The confirmed finding is undeclared pharmaceutical exposure, not a quantified overdose.

Why This Fits a Broader MedicalToxic Pattern

MedicalToxic has documented other products in which marketed identity failed to reflect the actual pharmacologic exposure.

In FDA Finds Toxic Yellow Oleander in Three Weight-Loss Products, Raising Digoxin-Like Poisoning Risk, FDA testing identified hidden diclofenac in DMagic Plus alongside a separate cardiac-glycoside hazard.

Similarly, FDA Finds Hidden Sildenafil and Tadalafil in Two Sexual-Enhancement Products shows how undeclared prescription drugs can remove medication-reconciliation safeguards.

Ort-Flx and RX7 add a distinct problem to that cluster:

the hidden corticosteroid may matter not only while the product is being taken, but also when a repeated exposure is stopped.

What Consumers Should Do

FDA advises consumers not to purchase or use Ort-Flx or RX7 Articulaciones.

For people already taking either product, FDA specifically recommends contacting a healthcare professional to discontinue use safely and to assess potential corticosteroid-withdrawal risk.

Suspected adverse reactions can be reported through FDA MedWatch.

Because the actual dose and duration of hidden dexamethasone exposure are unknown, consumers should not assume that a one-size-fits-all discontinuation plan applies.

What Is Genuinely New?

FDA has issued many previous hidden-ingredient warnings for pain and arthritis products.

The October 28 event is worth a dedicated consolidated News article because both products contain the same hidden NSAID/corticosteroid combination, and one also contains methocarbamol.

The information gain is therefore the combined pattern:

hidden diclofenac → unrecognized NSAID exposure

hidden dexamethasone → systemic corticosteroid exposure + possible withdrawal issue after sustained use

hidden methocarbamol in Ort-Flx → sedation, dizziness and hypotension

FDA's recommendation that current users seek medical guidance before discontinuation makes the hidden steroid especially clinically important.

Limitations and Remaining Unknowns

FDA has not reported concentrations of any of the undeclared drugs.

The notifications do not establish that consumers have developed adrenal insufficiency, GI bleeding, kidney injury, myocardial infarction, hypotension or another specific adverse outcome from Ort-Flx or RX7 Articulaciones.

They also do not establish how many people used either product.

The findings should not be generalized to all arthritis supplements, herbal products or pain-relief products sold online.

FDA itself notes that its public list represents only a fraction of contaminated products that may be on the market.

Conclusion

FDA laboratory testing has confirmed that Ort-Flx and RX7 Articulaciones contain prescription drugs that do not appear on their labels.

Both contain diclofenac and dexamethasone.

Ort-Flx additionally contains methocarbamol.

The central toxicology issue is therefore not simply hidden pain medication.

Consumers may unknowingly receive an NSAID, a systemic corticosteroid and—in Ort-Flx—a sedating muscle relaxant.

The hidden dexamethasone creates a particularly important medication-safety problem because FDA advises current users to seek professional guidance on safe discontinuation and potential corticosteroid withdrawal.

FDA currently classifies both actions as public notifications, not recalls.

References

1. U.S. Food and Drug Administration. (2026, October 28).
Ort-Flx may be harmful due to hidden ingredients

2. U.S. Food and Drug Administration. (2026, October 28).
RX7 Articulaciones may be harmful due to hidden ingredients

3. DailyMed, U.S. National Library of Medicine.
Dexamethasone tablet — prescribing information

4. U.S. Food and Drug Administration.
Health Fraud Product Database

5. U.S. Food and Drug Administration.
Pain and Arthritis Products Containing Hidden Ingredients